换一批NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen.
第一作者：
Matthew,Dyer
作者：
医学主题词
雄甾烯类(Androstenes);雄甾烯醇类(Androstenols);抗肿瘤药, 激素(Antineoplastic Agents, Hormonal);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);阉割(Castration);费用效益分析(Cost-Benefit Analysis);药费支出(Drug Costs);循证医学(Evidence-Based Medicine);人类(Humans);男(雄)性(Male);诊疗准则(主题)(Practice Guidelines as Topic);泼尼松龙(Prednisolone);前列腺肿瘤(Prostatic Neoplasms);质量校正寿命(Quality-Adjusted Life Years);紫杉烷类(Taxoids);临终医护(Terminal Care);时间因素(Time Factors);治疗结果(Treatment Outcome)
DOI
10.1016/s1470-2045(12)70289-9
PMID
23024987
发布时间
2019-10-27
- 浏览10
The Lancet. Oncology
762-3页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
